Assessing Incyte (INCY) Valuation After Strong Recent Share Price Momentum

Simply Wall St.

Jun 10

AdvertisementWhat recent returns tell you about Incyte (INCY) With no single headline event driving attention, investors are looking at Incyte (INCY) mainly through its recent performance, including a...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2642230447"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642230447\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642230447?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-10 17:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642230447","market":"us","top_or_hot":-1,"title":"Assessing Incyte (INCY) Valuation After Strong Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat recent returns tell you about Incyte (INCY) With no single headline event driving attention, investors are looking at Incyte (INCY) mainly through its recent performance, including a...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/assessing-incyte-incy-valuation-after-strong-recent-share-pr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Incyte (INCY) Valuation After Strong Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Incyte (INCY) Valuation After Strong Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-10 17:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/assessing-incyte-incy-valuation-after-strong-recent-share-pr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat recent returns tell you about Incyte (INCY) With no single headline event driving attention, investors are looking at Incyte (INCY) mainly through its recent performance, including a...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/assessing-incyte-incy-valuation-after-strong-recent-share-pr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/assessing-incyte-incy-valuation-after-strong-recent-share-pr","article_id":"2642230447","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/assessing-incyte-incy-valuation-after-strong-recent-share-pr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2642230447","pubTimestamp":1781083289,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What recent returns tell you about Incyte (INCY)\nWith no single headline event driving attention, investors are looking at Incyte (INCY) mainly through its recent performance, including a 2.6% move over the past day and a 4.7% gain over the past month.\nSee our latest analysis for Incyte.\nBeyond the latest move, the 11.9% 7 day share price return and 9.1% 90 day share price return sit alongside a 47.3% 1 year total shareholder return. This points to momentum that has been building rather than...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4532":"文艺复兴科技持仓","INCY":"因塞特医疗","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4550":"红杉资本持仓"},"translate_title":"在近期股价强劲势头后评估Incyte(INCY)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1.5},"content_text":"AdvertisementWhat recent returns tell you about Incyte (INCY) With no single headline event driving attention, investors are looking at Incyte (INCY) mainly through its recent performance, including a 2.6% move over the past day and a 4.7% gain over the past month. See our latest analysis for Incyte. Beyond the latest move, the 11.9% 7 day share price return and 9.1% 90 day share price return sit alongside a 47.3% 1 year total shareholder return. This points to momentum that has been building rather than fading. If you are comparing Incyte with other potential opportunities in healthcare, this is a useful moment to widen your search and check out 39 healthcare AI stocks With the stock up 47.3% over the past year and recently trading at about a 5% discount to the average analyst price target of US$108.61, the real question is whether Incyte is still mispriced or if the market is already factoring in future growth. Most Popular Narrative: 4.9% Undervalued Incyte's most followed narrative pegs fair value at $108.50, a touch above the last close of $103.23, framing recent gains against a still modest discount.  The upcoming launches and label expansions of innovative therapies like Opzelura (ruxolitinib cream), povorcitinib, and Niktimvo in high-value indications such as atopic dermatitis, vitiligo, hidradenitis suppurativa (HS), and GVHD, along with a late-stage pipeline of targeted drugs, are described as positioning Incyte to benefit from heightened demand for advanced immunology and oncology treatments as global populations age, which the narrative suggests may support sustained revenue growth and future earnings.  Read the complete narrative. Curious what keeps that valuation above the market price? The narrative leans heavily on measured revenue expansion, margin pressure, and a richer future earnings multiple.  Result: Fair Value of $108.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that story can change quickly if Jakafi faces sharper than expected patent pressure, or if key late stage trials and launches encounter delays or disappointing data. Find out about the key risks to this Incyte narrative. Another way to look at valuation The popular narrative leans on future earnings and a higher P/E multiple, but the SWS DCF model comes out very differently. On that view, Incyte at $103.23 sits above an estimated future cash flow value of $52.57, which frames the stock as expensive rather than 4.9% undervalued. Which risk are you more comfortable with: paying up for a story, or trusting the cash flow math? Look into how the SWS DCF model arrives at its fair value. INCY Discounted Cash Flow as at Jun 2026Next Steps With sentiment split between upside potential and real risks, this is a good time to look through the data yourself and pressure test the story against your own expectations by reviewing the 2 key rewards and 1 important warning sign Looking for more investment ideas? If Incyte has your attention, do not stop here. Broaden your watchlist with other ideas that fit different goals using the Simply Wall Street Screener.  Target dependable income by reviewing companies in the 9 dividend fortresses that may suit a consistent cash flow focus. Hunt for potential bargains by scanning the screener containing 21 high quality undiscovered gems before other investors catch on. Prioritize resilience by checking companies in the 63 resilient stocks with low risk scores that may better match a conservative approach.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}